Sustained HIV-1 remission after heterozygous CCR5Δ32 stem cell transplantation

HIV cure is exceptionally rare, with only six cases documented among the estimated 88 million individuals who have acquired HIV since the onset of the epidemic<sup>1-6</sup>. Successful cures, including that of the pioneering individual known as the Berlin patient, are limited to those who received allogeneic stem cell transplants (allo-SCTs) for haematological cancers. HIV resistance from stem cell donors with the rare homozygous CCR5Δ32 mutation was long considered the main mechanism for HIV remission without antiretroviral therapy. However, recent reports have highlighted CCR5-independent mechanisms as important contributors to HIV cure<sup>6-8</sup>. Here we provide new evidence for this conceptual shift, whereby long, treatment-free HIV remission was achieved after allo-SCT with functionally active CCR5. A man with heterozygous CCR5 wild-type/Δ32 living with HIV received allo-SCT from a HLA-matched unrelated heterozygous CCR5 wild-type/Δ32 donor as treatment for acute myeloid leukaemia. Three years after allo-SCT, the patient discontinued antiretroviral therapy. So far, HIV remission has been sustained for more than 6 years with undetectable plasma HIV RNA. Reservoir analysis revealed intact proviral HIV before transplantation, but no replication-competent virus in blood or intestinal tissues after allo-SCT. Declining or absent HIV-specific antibody and T cell responses support the absence of viral activity. High antibody-dependent cellular cytotoxicity activity at the time of transplantation may have contributed to HIV reservoir clearance. These results demonstrate that CCR5Δ32-mediated HIV resistance is not essential for durable remission, which underscores the importance of effective viral reservoir reductions in HIV cure strategies.

Authors

Institutions

Publication Details

Journal
Nature
Published
2025-12-01
DOI
https://doi.org/10.1038/s41586-025-09893-0
Citations
5
Primary Topic
HIV Research and Treatment
Type
article
Field-Weighted Citation Impact
5.18
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Sustained HIV-1 remission after heterozygous CCR5Δ32 stem cell transplantation

Gerd Klausen, Axel Prüß, Marion Pardons, Jürgen Sauter et al.
5 citations
Nature
HIV Research and Treatment
5.18
article

Sustained HIV-1 remission after heterozygous CCR5Δ32 stem cell transplantation

Gerd Klausen, Axel Prüß, Marion Pardons, Jürgen Sauter, Henning Gruell, Philipp Schommers, Kristina Allers, Thomas Schneider, Thomas Burmeister, Kirsten Hanke, Timo Trenkner, Jörg Hofmann, Lam Vuong, Michela Perotti, Vanessa Igbokwe, Leif Erik Sander, Lars Bullinger, Livius Penter, Samad Kor, Martin Obermeier, Rachel Scheck, Karolin Meixenberger, Naomi Perkins, Olga Blau, Olaf Penack, Gülüstan Sürücü, David Mwangi, Angelique Hölzemer, Victor M. Corman, Christian Gaebler, Florian Klein, Daniel B. Reeves, Christian G. Schneider, Stanley Odidika, Yeqin Sha, Thomas Kraus, Igor W. Blau, Nikolai Grahn, Carmen Arentowicz
article en
5 citations

Abstract

HIV cure is exceptionally rare, with only six cases documented among the estimated 88 million individuals who have acquired HIV since the onset of the epidemic<sup>1-6</sup>. Successful cures, including that of the pioneering individual known as the Berlin patient, are limited to those who received allogeneic stem cell transplants (allo-SCTs) for haematological cancers. HIV resistance from stem cell donors with the rare homozygous CCR5Δ32 mutation was long considered the main mechanism for HIV remission without antiretroviral therapy. However, recent reports have highlighted CCR5-independent mechanisms as important contributors to HIV cure<sup>6-8</sup>. Here we provide new evidence for this conceptual shift, whereby long, treatment-free HIV remission was achieved after allo-SCT with functionally active CCR5. A man with heterozygous CCR5 wild-type/Δ32 living with HIV received allo-SCT from a HLA-matched unrelated heterozygous CCR5 wild-type/Δ32 donor as treatment for acute myeloid leukaemia. Three years after allo-SCT, the patient discontinued antiretroviral therapy. So far, HIV remission has been sustained for more than 6 years with undetectable plasma HIV RNA. Reservoir analysis revealed intact proviral HIV before transplantation, but no replication-competent virus in blood or intestinal tissues after allo-SCT. Declining or absent HIV-specific antibody and T cell responses support the absence of viral activity. High antibody-dependent cellular cytotoxicity activity at the time of transplantation may have contributed to HIV reservoir clearance. These results demonstrate that CCR5Δ32-mediated HIV resistance is not essential for durable remission, which underscores the importance of effective viral reservoir reductions in HIV cure strategies.

NatureVol. 650(8102)
The Center for Victims of Torture (US), Leibniz Institute of Virology (LIV) (DE), Universität Hamburg (DE), University of Cologne (DE), Robert Koch Institute (DE), Humboldt-Universität zu Berlin (DE), Fred Hutch Cancer Center (US), MSB Medical School Berlin (DE), University Medical Center Hamburg-Eppendorf (DE), Vivantes Klinikum (DE), National Center for Tumor Diseases (DE), German Center for Infection Research (DE), Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE), University Hospital Cologne (DE), Deutsche Knochenmarkspenderdatei (DE), Freie Universität Berlin (DE), Charité - Universitätsmedizin Berlin (DE)
Openalex Percentile: Top 5%
HIV Research and Treatment
5.18
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.